Difference between revisions of "Ibrutinib (Imbruvica)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 35: Line 35:
 
[[Category:Kinase inhibitors]]
 
[[Category:Kinase inhibitors]]
 
[[Category:BTK inhibitors]]
 
[[Category:BTK inhibitors]]
 +
[[Category:TEC inhibitors]]
  
 
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]]
 
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]]

Revision as of 21:32, 18 September 2015

General information

Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.[1][2][3] [4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

CRA-032765, PCI-32765

References